Skip to content
Screener

Vir Biotechnology, Inc. VIR Business Segments — Personnel

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Personnel
$3.62M-61.5%
Bakkt logo
BKKTReportable Segment — Personnel
$3.37M-31.8%
Hyliion logo
HYLNReportable Segment — Personnel
$7M+11.1%
Absci Corporation logo
ABSISegment One — Personnel
$9.25M-6.3%
Sachem Capital Corp. logo
SACHPersonnel
$1.94M+6.4%
Burford Capital logo
BURPersonnel
$4.12M-18.8%

Other financials

Income statement

See full
Revenue$238.9M+19,583%
Gross profit$238.9M+19,763%
Operating income$73.5M+162%
Net income$80.1M+172%
EPS (diluted)$0.47+159%

Balance sheet

See full
Cash & equivalents$287.6M-6.1%
Total debt$93.3M-8.8%
Total equity$982.5M+3.7%
Total assets$1.2B+1.9%

Cash flow

See full
Operating cash flow-$132.4M-69.5%
CapEx$32.0K-98.7%
Free cash flow-$132.8M-66.5%

Valuation

See full
Market cap$1.48B+111%
Enterprise value$1.29B+159%
P/S4.9×-32.1×

Profitability

See full
Gross margin96.1%-2.7pp
Operating margin-92.4%-45.5pp
Net margin-83%-40.9pp
FCF margin-686.5%-273pp

Returns & leverage

See full
Return on equity-26.1%-7.9pp
Debt / equity0.1×0.0×
Current ratio-1.0×

Where this comes from

Reported directly by Vir Biotechnology, Inc. in its filing.

Tagged under the XBRL concept vir:ResearchAndDevelopmentPersonnel.

The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053549
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of revenue1111
Research and development
Contract manufacturing23,96714,06359,97423,399
Personnel (2)28,51233,16560,04066,883
Clinical costs22,53220,36148,66640,967
Licenses, collaborations and contingent consideration, net41,21111,30138,40247,892
Other R&D (3)19,06118,61937,12337,013
Selling, general and administrative (2)30,19622,28353,53546,227

Item 1. Financial Statements (unaudited)

FAQ

What is Vir Biotechnology, Inc.'s business segments — personnel?
Vir Biotechnology, Inc. (VIR) reported business segments — personnel of $28.51M in Q2 2026.
How has Vir Biotechnology, Inc.'s business segments — personnel changed year-over-year?
Vir Biotechnology, Inc.'s business segments — personnel decreased by 14.0% year-over-year, from $33.17M to $28.51M.
What is the long-term trend for Vir Biotechnology, Inc.'s business segments — personnel?
Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s business segments — personnel has grown at a -7.3% compound annual growth rate (CAGR), from $157.17M to $125.27M.
What does business segments — personnel mean?
Captures the total compensation and benefits costs associated with the workforce dedicated to the specific business segment. This metric reflects the company's investment in human capital required to support research, development, and operational activities.

Ask your AI about Vir Biotechnology, Inc.'s business segments — personnel.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude